Drug-Linker Conjugates for ADC
Drug-Linker Conjugates for Antibody Drug Conjugates (ADCs) comprise of an active cytotoxic drug and an appropriate linker. After linked to a monoclonal antibody, those conjugates can be used for making ADCs, which are targeted agents for cancer cells with high selectivity and cytotoxicity.
The drug units in drug-linker conjugates are cytotoxic agents (i.e. ADC cytotoxins or payloads) with antitumor activity and can be classified in DNA damaging agents and tubulin inhibitors. The most commonly used DNA damaging agents in ADCs are Duocarmycins, Pyrrolobenzodiazepines, Camptothecins and Daunorubicins/Doxorubicins, while the popular tubulin inhibitors are Auristatins and Maytansinoids. Besides, there are also many traditional cytotoxic agents can be used in ADCs.
ADC linkers currently undergoing clinical evaluation are mostly classified into two categories: cleavable and noncleavable. Cleavable linkers rely on processes inside the cell to liberate the toxin, and noncleavable linkers require proteolytic degradation of the antibody portion of the ADC for release of the cytotoxic molecule.
Drug-Linker Conjugates for ADC Isoform Specific Products
-
Drug-Linker Conjugates for ADC
(327)
View all products
-
Auristatin
(45)
View all products
-
Camptothecins
(33)
View all products
-
Daunorubicins/
Doxorubicins (5)View all products
-
Duocarmycins
(8)
View all products
-
Maytansinoids
(19)
View all products
-
Pyrrolobenzodiazepines
(5)
View all products
-
Traditional Cytotoxic Agents
(31)
View all products
-
Dual payloads
(5)
View all products
All Product Categories
-
Drug-Linker Conjugates for ADC Related Products (500)
Related Products (500)
-
Drug-Linker Conjugates for ADC Isoform Comparison
-
Pan-RAS-IN-9-(R)-2-Hydroxy-3-methylbutanoic acid-Sar9-N-Lys(Tos)-βAla-GFGG
0 ImagesCat. No.: HY-186279CAS No.: 3135386-37-4Pan-RAS-IN-9-(R)-2-Hydroxy-3-methylbutanoic acid-Sar9-N-Lys (Tos)-βAla-GFGG is a drug-linker conjugate for antibody-drug conjugate (ADC) with pan-Ras inhibitory activity. Pan-RAS-IN-9-(R)-2-Hydroxy-3-methylbutanoic acid-Sar9-N-Lys (Tos)-βAla-GFGG can be used in research related to ADC synthesis.
-
Modified MMAF-C5-COOH
0 ImagesCat. No.: HY-141593CAS No.: 1404071-65-3Modified MMAF-C5-COOH is a agent-linker conjugate for ADC.
-
Mal-cyclohexane-Gly-Gly-Phe-Gly-Exatecan
0 ImagesCat. No.: HY-153067CAS No.: 2578019-72-2Mal-cyclohexane-Gly-Gly-Phe-Gly-Exatecan (Compound 11) is a bioactive compound-linker conjugate for ADC. Mal-cyclohexane-Gly-Gly-Phe-Gly-Exatecan can conjugate with antibodies to form ADC (C-11) with anti-tumor activity. Exatecan is a DNA Topoisomerase I inhibitor. Mal-cyclohexane-Gly-Gly-Phe-Gly-Exatecan can be used in the research of squamous cell carcinoma, pancreatic adenocarcinoma and colorectal cancer.
-
MC-Gly-Gly-Phe-Gly-NH-CH2-O-amide-Eribulin
0 ImagesCat. No.: HY-160683CAS No.: 2907719-55-3MC-Gly-Gly-Phe-Gly-NH-CH2-O-amide-Eribulin (Compound 7) can be used as a linker-drug intermediate for the synthesis of antibody-drug conjugates (ADCs).
-
(S,R,S)-MI-1061
0 ImagesCat. No.: HY-125858BCAS No.: 1410738-90-7(S,R,S)-MI-1061 is the isomer of MI-1061(HY-125858). (S,R,S)-MI-1061 can used to synthesize Antibody-Drug Conjugates (ADCs). MI-1061 is a potent, orally bioavailable, and chemically stable MDM2 (MDM2-p53 interaction) inhibitor (IC50=4.4 nM; Ki=0.16 nM). MI-1061 potently activates p53 and induces apoptosis in the SJSA-1 xenograft tumor tissue in mice. Anti-tumor activity.
-
NH2-Gly-PAB-Exatecan-D-glucuronic acid
0 ImagesCat. No.: HY-160885CAS No.: 2763252-31-7NH2-Gly-PAB-Exatecan-D-glucuronic acid (Compound 8) is an intermediate, which reacts with NHS group to form drug-linker conjugate for ADC, Mal-Gly-PAB-Exatecan-D-glucuronic acid (HY-153179).
-
TLR7 agonist 30
0 ImagesCat. No.: HY-173079TLR7 agonist 30 (compound 2) is an agent-linker conjugate for ADC. TLR7 agonist 30 contains a TLR7 agonist (compound 1) and a cleavable linker, and has potent anti-tumor activity.
-
Val-Cit-amide-Cbz-N(Me)-Maytansine
0 ImagesCat. No.: HY-156896CAS No.: 1628543-59-8Val-Cit-amide-Cbz-N(Me)-Maytansine is an antibody and bispecific antigen-binding mol. that bind hepatocyte growth factor receptor c-Met (MET) or antibody-drug conjugates (ADCs).
-
GGGFG-Eribulin
0 ImagesCat. No.: HY-184465CAS No.: 3093143-86-0
-
Fmoc-Gly-Gly-Phe-Gly-Paclitaxel
0 ImagesCat. No.: HY-181429CAS No.: 3061439-05-9Fmoc-Gly-Gly-Phe-Gly-Paclitaxel (Compound 16a-3) is a drug-linker conjugates for ADC. Fmoc-Gly-Gly-Phe-Gly-Paclitaxel contains the ADC linker Fmoc-Gly-Gly-Phe-OH (HY-131833) and a potent tubulin polymerization inhibitor Paclitaxel (HY-B0015). Fmoc-Gly-Gly-Phe-Gly-Paclitaxel can be used for the research of cancer.
-
Demethylation-desulfuration-α-Amanitin-OH-PAB-Ala-Val-CO-C2-mal
0 ImagesCat. No.: HY-182806Demethylation-desulfuration-α-Amanitin-OH-PAB-Ala-Val-CO-C2-mal is a conjugate of an ADC drug toxin molecule and a linker, containing a degradable PEG linker and the toxin molecule M-4, which is a cyclic peptide derived from α-Amanitin (HY-19610).
-
DMBA-SIL-Mal-MMAE
0 ImagesCat. No.: HY-160702CAS No.: 2923885-49-6DMBA-SIL-Mal-MMAE is a cytotoxin-linker conjugate for ADC with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked DMBA-SIL-Mal.
-
Mal-TLR7 agonist 32
0 ImagesCat. No.: HY-167966CAS No.: 2097377-92-7Mal-TLR7 agonist 32 is a drug-linker conjugate that consists of a TLR7 agonist (HY-167774) and a linker. Mal-TLR7 agonist 32 can be used in synthesis of ADC.
-
CCK2R Ligand-Linker Conjugates 1
0 ImagesCat. No.: HY-128941CAS No.: 1452145-13-9CCK2R Ligand-Linker Conjugates 1 is a ligand-linker conjugate, which conjugates to the cytotoxic antimicrotubule agents Desacetyl Vinblastine Hydrazide (DAVBH) and Tubulysin B Hydrazide (TubBH) via a hydrophilic peptide linker.
-
N-(NHS-PEG4)-N-(PEG4-Val-Cit-PAB-MMAF)-N-(PEG4-Val-Cit-PAB-Exatecan)
0 ImagesCat. No.: HY-177688N-(NHS-PEG4)-N-(PEG4-Val-Cit-PAB-MMAF)-N-(PEG4-Val-Cit-PAB-Exatecan) is a drug-linker conjugate for ADC (Drug-Linker Conjugate for ADC), consisting of a tubulin polymerization inhibitor MMAE (HY-15162) and a DNA topoisomerase I inhibitor Exatecan (HY-13631), and an ADC linker composition. N-(NHS-PEG4)-N-(PEG4-Val-Cit-PAB-MMAF)-N-(PEG4-Val-Cit-PAB-Exatecan) can be used for synthesis of ADCs and for cancer research.
-
TPA(bi(Tos))-γ-Glu(PEG23)-Gly-Gly-Gly-C2-NH-PNU-159682
0 ImagesCat. No.: HY-184522TPA (bi (Tos))-γ-Glu (PEG23)-Gly-Gly-Gly-C2-NH-PNU-159682 (Fig.4 B) is a conjugate of a toxin molecule and a linker, which can be used to synthesize ADCs. TPA (bi (Tos))-γ-Glu (PEG23)-Gly-Gly-Gly-C2-NH-PNU-159682 consists of the DNA alkylating/inserting agent PNU-159682 (HY-16700) and the linker (HY-184523).
-
ADC-VI
0 ImagesCat. No.: HY-176927CAS No.: 3031725-06-8ADC-VI (Compound 6) is a conjugate of a toxic molecule and a linker, in which the cytotoxin carried by CPD6 is Deruxtecan (HY-13631E). Tricyclene is used to form an antibody-drug conjugate (ADC) by a chemical conjugation reaction through linking with an anti-FGFR2b antibody.
-
W1507
0 ImagesCat. No.: HY-184905W1507 is an NH2-TML-based linker-payload conjugate, in which the payload is Exatecan (HY-13631) and the linker is Mal-PEG4-Val-Ala-Ph-2,2-dimethylpropanoic acid (HY-184906). W1507 can be conjugated with Trastuzumab (HY-P9907) to synthesize the ADC Her2-W1507. Her2-W1507 exhibits in vivo anti-tumor activity. W1507 can be used for the research of gastric cancer, ovarian adenocarcinoma and Her2-amplified breast cancer.
-
TLR7/8 agonist 12-PAB-(PEG4-Me)-Cit-Val-PEG2-amide-C2-MC
0 ImagesCat. No.: HY-176202CAS No.: 3080930-77-1TLR7/8 agonist 12-PAB-(PEG4-Me)-Cit-Val-PEG2-amide-C2-MC (compound LIV1-IMC (12) linker-payload) is a linker-payload conjugate, used in the synthesis of antibody-drug conjugates (ADCs).TLR7/8 agonist 12-PAB-(PEG4-Me)-Cit-Val-PEG2-amide-C2-MC contains TLR7/8 agonist (HY-170770) (ADC payload) and a linker (HY-176478).
